Metastatic Malignant Melanoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastatic malignant melanoma. 30 active patents protecting 2 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

2
Approved drugs
30
Active US patents
43/100
Avg vulnerability
$716M
Annual revenue covered

Originators in Metastatic Malignant Melanoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 30 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastatic malignant melanoma. Each bar = one year. Y-axis scaled to peak year (15 patents).

1
27
2
29
15
30
3
31
5
32
4
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Braftovi
encorafenib
 Pfizer 23 51 $716M 2029-07-23
Mektovi
binimetinib
 Pfizer 7 35 — 2027-03-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8541575 Braftovi method of use 68 2030-02-26
8541575 Braftovi method of use 68 2030-02-26
10005761 Braftovi method of use 68 2030-08-27
9850229 Braftovi method of use 68 2030-08-27
9850230 Braftovi method of use 68 2030-08-27
9850229 Braftovi method of use 68 2030-08-27
9850230 Braftovi method of use 68 2030-08-27
10005761 Braftovi method of use 68 2030-08-27
9314464 Braftovi method of use 68 2031-07-04
9314464 Braftovi method of use 68 2031-07-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9562016 Mektovi composition of matter 0 2033-10-18
7777050 Mektovi composition of matter 5 2027-03-13
9593099 Braftovi composition of matter 10 2030-08-27
9593099 Braftovi composition of matter 10 2030-08-27
8946250 Braftovi composition of matter 10 2029-07-23
8946250 Braftovi composition of matter 10 2029-07-23
RE49556 Braftovi composition of matter 18 2030-02-27
9387208 Braftovi formulation 42 2032-11-21
9387208 Braftovi formulation 42 2032-11-21
9598376 Mektovi method of use 45 2033-10-18

Related